Cingulate Inc. (CING)

0.8700 -0.0180 (-2.03%) As of 12:09PM EDT. Market open.

Cingulate Inc.

1901 West 47th Place
Kansas City, KS 66205
United States
913 942 2300
https://www.cingulate.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 13

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Shane J. Schaffer Pharm.D., PharmD	CEO & Chairman of the Board	491.96k	N/A	1975
Dr. Laurie A. Myers M.B.A., Ph.D.	Executive VP & COO	415.17k	N/A	1957
Dr. Matthew N. Brams M.D.	Executive VP & Chief Medical Officer	244.79k	N/A	1964
Ms. Jennifer L. Callahan CPA	Senior VP, CFO & Secretary	N/A	N/A	1971
Dr. Raul R. Silva M.D.	Executive VP & Chief Science Officer	N/A	N/A	1958
Thomas Dalton	Vice President of Investor & Public Relations	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Corporate governance

Cingulate Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.